Hard technology continues to heat up, with Zhijian Power raising a total of 2 billion yuan in financing over half a year.

Over the past week, the dual core pattern of technology and manufacturing, as well as healthcare, has continued to strengthen. The consumer services sector also showed impressive financing performance, with large transactions in segments such as embodied intelligence, brain-computer interfaces, AI video generation, and cell therapy.

In the technology and manufacturing sectors, large-scale investment and financing deals have been clustered: Embodied intelligence company Jizhuan Power completed a 2 billion RMB Series A funding round, attracting well-known investors including Yuanjing Capital, Sequoia China, and strategic investors like Tencent and Alibaba; MagicLab, also in embodied intelligence, completed over 500 million RMB in Series A funding, simultaneously launching a hundred-billion ecosystem fund, with core products including humanoid and quadruped robots already mass-produced and delivered; AI video generation company Aishi Technology completed a $300 million Series C funding round, focusing on building an AIGC visual multimodal algorithm platform covering various vertical application scenarios; Generative AI and simulation data provider Guanglun Intelligence completed a 1 billion RMB Series A+ round, using a “generative AI + simulation technology” integrated model to fill data gaps in the AI era.

Additionally, companies like BlueStar Light Domain, Zero One Automotive, Huaxin Cheng, and Yao Shi Lithium Battery have each completed over 100 million RMB in funding, covering segments such as satellite laser communication, intelligent driving new energy heavy trucks, chip design, and solid-state batteries. Capital continues to focus on core technologies that are autonomous and controllable, full industry chain deployment, and scenario-based implementation. Independent innovation has become the core development direction for companies after financing.

The healthcare sector maintains a steady and positive financing trend, with related deals in segments such as brain diagnosis and treatment, cell therapy, and cardiac electrophysiology: Brain-computer interface R&D company Ladder Medical completed 500 million RMB in strategic financing; cardiac electrophysiology company Aico Mai completed over 100 million RMB in Series B funding; next-generation universal spot cell therapy drug developer Aikai Biotech completed over 100 million RMB in Series A+++ funding; anti-aging and metabolic drug developer MetaNovas completed Series A+ and A++ rounds.

According to incomplete statistics from 21 Venture Capital, from March 9 to March 15, 2026, a total of 50 financing events were disclosed in the domestic primary market. Among them, 27 disclosed amounts and currencies, with a total disclosed financing scale exceeding 11 billion RMB.

01. Multiple financings completed in the technology, manufacturing, and healthcare sectors

This week’s financing mainly concentrated in the technology, manufacturing, healthcare, and consumer services sectors. The technology and manufacturing sector completed 36 deals, covering segments such as embodied intelligence and intelligent driving; healthcare completed 6 deals, including cell therapy and brain diagnosis equipment, demonstrating strong development potential.

02. Jiangsu Province, Guangdong Province, and Beijing completed multiple financings

From the regional distribution of invested companies, the main regions for financing this week were Jiangsu Province, Guangdong Province, and Beijing, with 15, 11, and 7 deals respectively.

03. Which investment institutions are more active

In terms of institutional investment activity, Songhe Capital and Fangguang Capital were particularly active this week, with most deals concentrated in the technology and manufacturing sectors.

Below is a summary of investment and financing information:

Healthcare

MetaNovas completes Series A+ and A++ rounds

On March 9, MetaNovas (Yuanxing Zhiyao) recently completed Series A+ and A++ rounds, jointly invested by Fuhua Capital, Hillhouse Capital, and Kangaroo Mom Group, among others in the consumer health industry. Previously, Series A was led by Hillhouse Venture Capital and Baoding Venture Capital, with follow-on investments from Yu Yuchen.

MetaNovas is a developer of anti-aging and metabolic drugs, aiming to combine AI with life sciences, using deep learning, knowledge graphs, and multi-omics analysis to understand complex biological networks, decipher disease mechanisms, and develop products such as anti-aging agents and treatments for neurodegenerative and metabolic diseases.

Aikai Biotech completes Series A+++ funding

On March 9, Aikai Biotech, a developer of next-generation universal spot cell therapy drugs, completed over 100 million RMB in Series A+++ funding, led by Wojie Capital, Zhiyi Investment, and Lianxin Capital. Previous investments included Zhiyi Investment and West Lake Venture Capital.

Aikai is a new generation of universal spot cell therapy developer, committed to “patient-centered, clinical demand-driven” drug R&D. It has deep technical expertise in iPSC reprogramming, gene editing, and stem cell differentiation, achieving a series of original breakthroughs in the iPSC field.

Zhongke Boxrui completes several tens of millions RMB in Series B funding

On March 10, Zhongke Boxrui, a brain diagnosis and treatment device developer, completed several tens of millions RMB in Series B funding, led by Sanzhe Venture Capital. Previous investors included Zhangjiagang Industrial Capital and Jinxin Capital.

Based on NIRS (Near Infrared Spectroscopy) principles and leveraging research from the Institute of Automation, Chinese Academy of Sciences, the company developed non-invasive, multi-channel, real-time monitoring portable brain oxygen monitors and wearable wireless brain oxygen headbands.

Ladder Medical completes 500 million RMB in Series C funding

On March 12, brain-computer interface R&D company Ladder Medical secured 500 million RMB in strategic financing, led by Alibaba, with Guotou Chuanghe and other investors participating. Major existing shareholders include Tencent, Yuanlai Capital, Aobo Capital, Yuanhe Yuan Dian, Qiming Venture Partners, Eli Lilly Asia Fund, Source Code Capital, and Shanghai Guotou Pioneer. The total financing in the past year has reached 1.1 billion RMB.

Founded in August 2021, Ladder Medical is an innovative tech company focused on implantable brain-machine interfaces. It aims to develop neural interfaces (electrodes), implantable brain-machine interface platforms, and translate related scientific achievements into clinical applications, targeting motor control, neural disease monitoring and regulation, and sensory restoration.

Aico Mai completes over 100 million RMB in Series B funding

On March 13, Aico Mai Medical completed over 100 million RMB in Series B funding, led by China International Capital Corporation (CICC) funds, with Yuanjing Capital and industry investors participating. The funds will accelerate R&D and commercialization of pulse electric field ablation systems, 3D mapping systems, and electrophysiology consumables, strengthening its position in cardiac electrophysiology innovation.

Aico Mai focuses on cardiac electrophysiology and structural heart disease intervention, aiming to become a leading global platform for electrophysiology innovation. The company has R&D centers in both China and the US, with core team members from Johnson & Johnson, Abbott, Medtronic, and other global firms, with strong technical and industrialization experience.

02. Technology and manufacturing

Ouka Zhihuo completes nearly 2 billion RMB in Series B+ funding

On March 9, Ouka Zhihuo, a developer of surface unmanned vessels and surface service robots, announced the completion of nearly 2 billion RMB in Series B+ funding, led by Houxue Capital and Yuanhe Chongyuan. Previous investors included Gobi Bay Area and Tianshan Capital.

Ouka Intelligent specializes in environmentally friendly surface unmanned ships, made from high-strength fiberglass composites with features like corrosion resistance, wear resistance, and microwave transparency. Its vessels support applications such as surface cleaning, water quality testing, water treatment, surface inspection, and water area mapping.

Huaxin Cheng completes over 3 billion RMB in Series A+ funding

On March 9, Huaxin Cheng, a chip design service provider, announced the completion of over 3 billion RMB in Series A+ funding, invested by Pudong Venture Capital, Lingang Sci-Tech Venture Capital, and Shanghai Integrated Circuit Industry Fund. Previous investors included Goxin Capital and SMIC Xicheng.

BlueStar Light Domain completes nearly 5 billion RMB in Series C funding

On March 10, BlueStar Light Domain, a developer of satellite laser communication terminals, announced nearly 5 billion RMB in Series C funding, led by Yuekai Capital and Galaxy Innovation Capital. Previous investors included Xiyang Capital, Guoxin High-Level Talent Fund, and Guangzhou Industrial Investment Group.

Guanglun Intelligence completes 1 billion RMB in Series A+ funding

On March 11, Guanglun Intelligence, a provider of generative AI and simulation data, announced 1 billion RMB in Series A+ funding, led by New Hope Group and Dingbang Investment. Previous investors included Dongfang Fuhai and Sanqi Interactive Entertainment Venture Capital.

Founded in 2023, Guanglun aims to provide automated, physically precise, controllable, realistic, and generalizable synthetic data solutions for enterprise AI deployment. It integrates generative AI with simulation technology to produce high-quality, large-scale, low-cost multimodal synthetic data, addressing data gaps in the AI era.

Qianxing Innovation completes nearly 100 million RMB in Series C funding

On March 11, Shenzhen Qianxing Innovation Technology Co., Ltd. (Qianxing Innovation) completed nearly 100 million RMB in Series C funding, led by Lihui Capital. The funds will be used for core technology R&D, key product iteration, supply chain and manufacturing upgrades, overseas market expansion, and industry scenario solutions.

Founded in 2016, Qianxing Innovation is a global underwater intelligent equipment company focusing on industry and consumer-grade underwater robots, portable underwater intelligent unmanned equipment, and related solutions. It is also a national “Little Giant” enterprise recognized for specialized and innovative capabilities.

Aishi Technology completes $300 million Series C funding

On March 12, AI video generation company Aishi Technology announced $300 million in Series C funding, led by Dinghui Hong Kong Fund, Dinghui VGC, and Dinghui Baifu, with industry investors China Ruyi, Sanqi Interactive Entertainment, and others participating.

Aishi aims to build a visual multimodal algorithm platform centered on AIGC, covering various vertical visual applications. The team intends to serve the entire content production value chain through AI video generation, enhancing efficiency in content creation, security, analysis, distribution, and commercialization, ultimately developing AI-native video products.

Zhongke Optoelectronics completes nearly 400 million RMB in Series A funding

On March 13, Zhongke Optoelectronics, an industrial robot company, announced nearly 400 million RMB in Series A funding, led by Donghai Investment and Baichuan Energy. Previous investors included Dongfang Jiafu and Shanda Investment.

Supported by the Xi’an Institute of Optics and Mechanics, Chinese Academy of Sciences, and Zhongke Chuangxing, the company specializes in precision optical components for aerospace and aviation, with core technical teams from CAS. It leverages major national projects to develop a new intelligent theoretical framework based on embodied cognition, using stereo vision sensing to solve fine visual recognition of arbitrary three-dimensional objects.